James Kuo, MD, MBA

CHAIRMAN

Committee Served: Finance

Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Dr. Jennifer Bath

President & CEO, Director

Committees Served: Finance & Compensation

Jennifer holds a Ph.D. in Cellular and Molecular biology from North Dakota State University; she began her career in academia, and moved into industry after a 15-year appointment as an Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute; whose mission is to prevent and treat neglected tropical diseases. Dr. Bath has broad experience in vaccine and therapeutic design, development and testing. Having served many guidance roles in industry, including advising on the Economic Development Corporation’s Strategic Planning Initiatives, consulting biotechnology and pharmaceutical companies on strategic and operational business practices, and providing governance for workshops in technology entrepreneurship; she has established relationships with leaders in the fields of therapeutics and vaccinology, enhancing collaborative developments and partnerships in discovery.

Dr. Bath served in an executive role at Aldevron, LLC, as the Global Director of Client Relations, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services.

Paul Andreola

Director

Committees Served: Compensation & Nomination

Paul Andreola has over 20 years of business development and financial markets experience including senior management, marketing, and communications roles for early stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over 10 years and has facilitated multiple early stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of Brisio Innovations Inc. (CSE: BZI) and Ironwood Capital Corp. (TSXV: IRN.P).

Greg Smith

Director

Committees Served: Finance & Compensation

Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).

Dr. Robert D. Burke

Director

Committees Served: Finance & Nomination

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for 8 years, was on the University of Victoria Senate for 12 years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.

Robert Beecroft

FOUNDER AND DIRECTOR

Committee Served: Nomination

Robert Beecroft is the founder of ImmunoPrecise and previously served as its Chief Executive Officer, Chief Technical Officer, and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 research projects over the course of the last 25 years, and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years.  In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.

Dr. Andrew E. Nixon

Director

Dr. Nixon currently serves as Vice President of Molecule Discovery at Boehringer Ingelheim. In this role he is responsible for supporting early biologic discovery activities. Prior to joining Boehringer Ingelheim Andy spent 17 years at Dyax including four years as Head of Research and most recently was at Magenta Therapeutics a stem cell transplant company.